Table 6.

Treatment selection: Proportion of therapies for post-menopausal ER+, HER2- metastatic BC patients used in first-line, second-line and third-line in the past 6 months – from physician survey (n = 103)

	First Line		Second Line		Third Line
Treatment	Mean	SD	Mean	SD	Mean	SD
Oral hormonal therapy (e.g., tamoxifen, aromatase inhibitors)	51.91%	32.48	21.14%	22.40	12.55%	15.02
Other hormonal (e.g., fulvestrant)	11.68%	17.54	21.66%	23.76	16.32%	19.98
Chemotherapy	17.55%	18.43	25.58%	23.12	35.83%	27.27
Exemestane plus Everolimus	9.50%	14.44	22.38%	24.41	21.26%	23.71
Avastin plus chemotherapy	4.19%	9.73	4.91%	10.44	6.17%	14.42
Clinical trial	1.90%	6.16	2.34%	6.20	3.89%	9.27
Other	3.25%	-	2.00%	-	3.97%	-

BC Breast cancer; SD standard deviation